相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
Mahiuddin Ahmed et al.
FEBS LETTERS (2014)
Cross-platform comparison of glycan microarray formats
Linlin Wang et al.
GLYCOBIOLOGY (2014)
Affinity maturation of a CDR3-grafted VHH using in silico analysis and surface plasmon resonance
Hidetoshi Inoue et al.
JOURNAL OF BIOCHEMISTRY (2013)
In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
Mahiuddin Ahmed et al.
PLOS ONE (2013)
Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy
Takeshi Nakanishi et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Nai-Kong V. Cheung et al.
NATURE REVIEWS CANCER (2013)
Engineering antibodies by yeast display
Eric T. Boder et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy
L. G. Durrant et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Nidale Tarek et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
Nai-Kong V. Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor
Irene Y. Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display
Christian Votsmeier et al.
MABS (2012)
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
Nai-Kong V. Cheung et al.
ONCOIMMUNOLOGY (2012)
Affinity Maturation to Improve Human Monoclonal Antibody Neutralization Potency and Breadth against Hepatitis C Virus
Yong Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Structures, Biosynthesis, and Functions of Gangliosides-an Overview
Robert K. Yu et al.
JOURNAL OF OLEO SCIENCE (2011)
Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity
Qi Zhao et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Beyond natural antibodies: the power of in vitro display technologies
Andrew R. M. Bradbury et al.
NATURE BIOTECHNOLOGY (2011)
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
F. Navid et al.
CURRENT CANCER DRUG TARGETS (2010)
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
Suzanne Shusterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody
Jian Hu et al.
JOURNAL OF IMMUNOLOGY (2009)
One-step expression and purification of single-chain variable antibody fragment using an improved hexahistidine tag phagemid vector
Qi Zhao et al.
PROTEIN EXPRESSION AND PURIFICATION (2009)
Affinity maturation of antibodies assisted by in silico modeling
Rodrigo Barderas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin
Consuelo Garcia-Rodriguez et al.
NATURE BIOTECHNOLOGY (2007)
Isolating and engineering human antibodies using yeast surface display
Ginger Chao et al.
NATURE PROTOCOLS (2006)
Crystal structure of an in Vitro affinity- and specificity-matured anti-testosterone Fab in Comiplex with testosterone -: Improved affinity results from small structural changes within the variable domains
J Valjakka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Structure of an anti-blood group A Fv and improvement of its binding affinity without loss of specificity
R Thomas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Maximizing the response to Herceptin® therapy through optimal use and patient selection
B Leyland-Jones
ANTI-CANCER DRUGS (2001)
Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
BH Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
